HIT-CF
Project ID: 755021
Funded under: H2020-EU.3.1.3. - Treating and managing disease

Personalised Treatment For Cystic Fibrosis Patients With Ultra-rare CFTR Mutations (and beyond)

From 2018-01-01 to 2022-12-31, ongoing project

**Project details**

<table>
<thead>
<tr>
<th>Total cost:</th>
<th>Topic(s):</th>
</tr>
</thead>
<tbody>
<tr>
<td>EUR 8 753 615</td>
<td>SC1-PM-08-2017 - New therapies for rare diseases</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EU contribution:</th>
<th>Call for proposal:</th>
</tr>
</thead>
<tbody>
<tr>
<td>EUR 6 701 365</td>
<td>H2020-SC1-2017-Two-Stage-RTD</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Coordinated in:</th>
<th>Funding scheme:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Netherlands</td>
<td>RIA - Research and Innovation action</td>
</tr>
</tbody>
</table>

**Objective**

In our HIT-CF project, we aim to bring personalised disease modifying therapies to cystic fibrosis (CF) patients with ultra-rare CFTR mutations, who could otherwise never get access to such treatment. Once we have proven our unique concept, the CF community can easily extend our state-of-the-art methodology to all CF patients such that HIT-CF will impact the entire CF field.

We will achieve our goals by means of a randomised, double-blind, placebo-controlled, repeated-crossover, three-armed platform trial with prospectively defined meta-analysis to evaluate efficacy at group and individual level. HIT-CF is designed to enable access to the most relevant global drug products, and each trial arm will test a drug product candidate (a single compound or a compound combination) from one of our pharmaceutical consortium partners. The patients will be assigned to the specific trial based on the effect of the drug product candidates on cultured intestinal miniature organs (termed organoids) grown from rectal biopsies, instead of based on typical genotyping only.

In parallel with this H2020 project, our pharmaceutical partners will obtain market approval of their drug product candidates for common (F508del or gating) mutations in the CFTR gene. Ultimately, our project will enable ‘managed’ off-label access to these therapies towards patient groups or individuals who show response to the therapy in a prospective intestinal organoid test.

One of the major impacts of this project will be the innovative methodologies to acquire reimbursement for current and future off-label treatments of people with CFTR mutations. This will represent a real paradigm shift in CF treatment as it implements a new type of personalized medicine paradigm based on organoids, by shifting therapeutic trials from patients to the laboratory.
### Coordinator

UNIVERSITAIR MEDISCH CENTRUM UTRECHT  
HEIDELBERGLAAN 100  
3584 CX UTRECHT  
Netherlands  
**EU contribution:** EUR 1 434 417.50

**Activity type:** Higher or Secondary Education Establishments  
Contact the organisation

### Participants

**EUROPEAN CYSTIC FIBROSIS SOCIETY**  
KASTANIEPARKEN 7  
7470 KARUP  
Denmark  
**EU contribution:** EUR 334 740

**Activity type:** Other  
Contact the organisation

**PATERGRUS BVBA**  
SPARHÖKEDREEF 57  
9880 AALTER  
Belgium  
**EU contribution:** EUR 302 075

**Activity type:** Private for-profit entities (excluding Higher or Secondary Education Establishments)  
Contact the organisation

**STICHTING HUBRECHT ORGANOID TECHNOLOGY**  
YALELAAN 62  
3584 CM UTRECHT  
Netherlands  
**EU contribution:** EUR 1 088 050

**Activity type:** Other  
Contact the organisation

**CYSTIC FIBROSIS EUROPE EV**  
IN DEN DAUEN 6  
53117 BONN  
Germany  
**EU contribution:** EUR 141 312.50

**Activity type:** Other  
Contact the organisation
FCIENCIAS.ID - ASSOCIACAO PARA A INVESTIGACAO E DESENVOLVIMENTO DE CIENCIAS
CAMPO GRANDE, EDIFICIO C1, PISO 3
1749 016 LISBON
Portugal

**Activity type:** Research Organisations

**EU contribution:** EUR 257,367.50

---

KATHOLIEKE UNIVERSITEIT LEUVEN
Oude Markt 13
3000 LEUVEN
Belgium

**Activity type:** Higher or Secondary Education Establishments

**EU contribution:** EUR 386,250

---

FLATLEY DISCOVERY LAB LLC
35 BRAINTEER HILL OFFICE PARK, SUITE 200
02184 BRAINTEER, MASSACHUSETTS
United States

**Activity type:** Other

**EU contribution:** EUR 27,000

---

JULIUS CLINICAL RESEARCH BV
BROEDERPLEIN 41-43
3703 CD ZEIST
Netherlands

**Activity type:** Private for-profit entities (excluding Higher or Secondary Education Establishments)

**EU contribution:** EUR 2,703

---

GALAPAGOS
GENERaal de WITTELAAN L11 A3
2800 MECHelen
Belgium

**Activity type:** Private for-profit entities (excluding Higher or Secondary Education Establishments)

**EU contribution:** EUR 27,000

---

**Last updated on** 2018-01-23

**Retrieved on** 2018-10-11

**Permalink:** https://cordis.europa.eu/project/rcn/212684_en.html